Business Wire

NY-PHILIP-MORRIS-INTL

19.1.2021 10:54:46 CET | Business Wire | Press release

Share
PMI’s Charles Bendotti Recognized by INvolve and Yahoo Finance on OUTstanding 50 Ally Executives List 2020; Nikki Symmons named on LGBT+ Future Leader List 2020

Charles Bendotti, Senior Vice President, People & Culture at Philip Morris International Inc. (PMI) (NYSE:PM), has today been recognized for his unwavering support for LGBTQ+ inclusion in the workplace, included on INvolve and Yahoo Finance’s OUTstanding 50 Ally Executives List 2020. The designation places Bendotti among a select group of business leaders and allies of LGBTQ+ inclusion recognized for driving cultural change within the workplace to create more inclusive environments across the world. Nikki Symmons, Content Planner, Global Communications at PMI, has also been named on the OUTstanding LGBT+ Future Leader List 2020 in recognition of her achievements in furthering LGBTQ+ inclusion both within PMI and beyond.

“I’ve been fortunate to have lived and led in many countries throughout my career, working with people from a variety of backgrounds and cultures who have taught me the value of inclusion and diversity first-hand,” said Bendotti. “I’m honored to be recognized as a global ally and included on the OUTstanding 50 Ally Executives List this year. As leaders it’s critical that everyone—without exception—feels valued, respected, and empowered to succeed.”

Bendotti’s recognition stems from his efforts in championing inclusion and diversity (I&D) within PMI and beyond. He was instrumental in championing the appointment of the company’s first Chief Diversity Officer, Silke Muenster, in March 2020; a role that reports directly to the CEO. Additionally, he is actively involved in advancing LGBTQ+ inclusion within the organization as executive sponsor of PMI’s global employee resource group, STRIPES, which aims to create a safe space for learning, sharing, allyship, and support to members and allies of the LGBTQ+ community.

Suki Sandhu OBE, founder, and CEO of INvolve, the consultancy and global network championing diversity and inclusion in business, said: “I’m thrilled to be celebrating another amazing group of LGBT+ and Ally role models from across the globe who are championing inclusion and inspiring the next generation of talent. LGBT+ discrimination is still prevalent across the world, and role models are essential to change perceptions and show everyone that you can be successful in business while also being your authentic self at work.”

For inclusion on the OUTstanding 50 Ally Executives List 2020, nominees’ seniority and influence were taken into consideration and their impact on LGBTQ+ inclusion inside and outside the workplace, as well as business achievements. They must be a vocal ally, actively working to create an environment where LGBTQ+ people can comfortably bring their best professional selves to work.

OUTstanding’s judging panel consisted of Lord Browne, executive chairman, L1 Energy; Ashok Vaswani, global consumer and payments head, Barclays; Harriet Green, former chairman and CEO, IBM Asia Pacific; Dawn Airey, independent director, Grosvenor Estates GBI; Jim Fitterling, CEO of Dow Inc.; Suki Sandhu OBE, founder and CEO, INvolve and Audeliss; and Lianna Brinded, head of Yahoo Finance UK.

The full list of nominees can be viewed here . For more information on PMI’s I&D efforts, click here .

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables to Altria Group, Inc. for sale under license in the U.S., where the U.S. Food and Drug Administration (FDA) has authorized their marketing as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of Sept. 30, 2020, PMI estimates that approximately 11.7 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 61 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .

About INvolve and OUTstanding

OUTstanding is part of INvolve, the consultancy and global network championing diversity and inclusion in business. Through the delivery of events, programs, thought leadership, and advisory services, INvolve helps firms drive cultural change and create inclusive workplaces where any individual can succeed. INvolve also publishes EMpower, HERoes, and OUTstanding role model lists annually, recognizing and celebrating business leaders and future leaders who are breaking down barriers at work and inspiring the next generation of diverse talent. For more information, please visit www.involvepeople.org

# # #

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye